GRI Bio(GRI) - 2021 Q3 - Quarterly Report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________________ FORM 10-Q ____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 For the transition period from_________to_________ Commission File Number: 001-40034 ____________________________________ VALLON PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified ...